TWO MUTATIONS IDENTIFIED IN THE ANDROGEN RECEPTOR OF THE NEW HUMAN PROSTATE CANCER CELL LINE MDA PCA 2A
- 1 December 1999
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 162 (6), 2192-2199
- https://doi.org/10.1016/s0022-5347(05)68158-x
Abstract
Purpose: We have characterized the androgen receptor (AR) in a new human prostate cancer cell line, MDA PCa 2a, that has recently been established from a bone metastasis of a patient whose cancer exhibited androgen-independent growth. Materials and Methods: Androgen responsiveness of these cells was assessed by measuring the effect of DHT and R1881 on cell growth and PSA secretion. Scatchard analysis was used to characterize the affinity and abundance of AR protein. Using a PCR based strategy, genomic DNA of the entire coding region of AR gene was sequenced to identify possible mutations. Results: These cells express abundant AR (Nmax = 685 ± 149 fmol./mg. protein), but the AR binding affinity (K d) for DHT is only 25 nM, ∼50-fold lower affinity than the mutated AR in LNCaP prostate cancer cells (K d = 0.5 nM) or the wildtype AR in MCF-7 breast cancer cells (K d = 0.4 nM). Two mutations, L701H and T877A, were identified in the ligand binding domain of the AR gene. Compared with LNCaP cells, the new cell line is significantly less responsive to DHT and R1881 as well as to other androgens such as testosterone, androstenedione, and DHEA. Similar to LNCaP cells, the ligand specificity of the AR in MDA PCa 2a cells appears to be relaxed and non-androgens such as progesterone and estradiol act as agonists although with less potency than in LNCaP cells. Interestingly, in the absence of androgens, the new cell line expresses 15-fold higher baseline levels of PSA than LNCaP. Conclusions: Two mutations were identified in the AR gene of the MDA PCa 2a cell line that are likely responsible for the decreased androgen sensitivity and altered ligand specificity observed in these cells. Thus, this new cell line with partial androgen responsiveness and PSA expression can serve as a functionally relevant model system of bone metastatic prostate cancer, and can be used to investigate the role of AR mutations in prostate cancer and its progression to androgen independence.Keywords
This publication has 10 references indexed in Scilit:
- The Androgen Receptor Gene Mutations DatabaseNucleic Acids Research, 1998
- Target to apoptosis: A hopeful weapon for prostate cancerThe Prostate, 1997
- 1 ,25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-DependentEndocrinology, 1997
- In vivo amplification of the androgen receptor gene and progression of human prostate cancerNature Genetics, 1995
- Androgen receptor gene mutations in human prostate cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for progestagenic and estrogenic steroidsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1990
- Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity.Proceedings of the National Academy of Sciences of the United States of America, 1989
- Comparative studies of 5α-reductase inhibitors within MCF-7 human breast cancer cellsJournal of Steroid Biochemistry, 1984
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acidBiochemical Journal, 1956